Literature DB >> 25974389

Association between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis.

G Bellini1, A N Olivieri, A Grandone, M Alessio, M F Gicchino, B Nobili, L Perrone, S Maione, E Miraglia del Giudice, F Rossi.   

Abstract

OBJECTIVES: To investigate whether the functional variant Q63R of the cannabinoid 2 (CB2) receptor is associated with susceptibility to oligo/poly-articular juvenile idiopathic arthritis (JIA) and with its clinical features.
METHOD: A total of 171 Italian children with oligoarticular/rheumatoid factor negative poly-articular JIA and 600 healthy controls were enrolled in the study and genotyped.
RESULTS: A significant difference in genotype distribution of the CB2 Q63R variant (CNR2 rs35761398) between oligo/poly-articular JIA patients and controls was found (p = 0.001). The R63 variant was associated with increased rates of relapse (p = 0.0001).
CONCLUSIONS: This study indicates that the CB2 receptor contributes to susceptibility to oligo/polyarticular JIA and to the severity of its clinical course.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25974389     DOI: 10.3109/03009742.2015.1020863

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  9 in total

1.  Study of cannabinoid receptor 2 Q63R gene polymorphism in Lebanese patients with rheumatoid arthritis.

Authors:  Morouj Ismail; Ghada Khawaja
Journal:  Clin Rheumatol       Date:  2018-07-21       Impact factor: 2.980

Review 2.  Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

Authors:  Francesca Rossi; Chiara Tortora; Maura Argenziano; Alessandra Di Paola; Francesca Punzo
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 3.  The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.

Authors:  Maura Argenziano; Chiara Tortora; Giulia Bellini; Alessandra Di Paola; Francesca Punzo; Francesca Rossi
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

4.  Biased Coupling to β-Arrestin of Two Common Variants of the CB2 Cannabinoid Receptor.

Authors:  Gábor Turu; Eszter Soltész-Katona; András Dávid Tóth; Cintia Juhász; Miklós Cserző; Ádám Misák; András Balla; Marc G Caron; László Hunyady
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-16       Impact factor: 5.555

5.  Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.

Authors:  Mostafa Rastegar; Saeed Samadizadeh; Mohammad Yasaghi; Abdolvahab Moradi; Alijan Tabarraei; Vahid Salimi; Alireza Tahamtan
Journal:  Arch Virol       Date:  2021-09-13       Impact factor: 2.574

Review 6.  Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.

Authors:  Marta Bryk; Katarzyna Starowicz
Journal:  Pharmacol Rep       Date:  2021-05-28       Impact factor: 3.024

7.  The Cannabinoid Receptor 2 Q63R Variant Modulates the Relationship between Childhood Obesity and Age at Menarche.

Authors:  Giulia Bellini; Anna Grandone; Marco Torella; Emanuele Miraglia del Giudice; Bruno Nobili; Laura Perrone; Sabatino Maione; Francesca Rossi
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

8.  Endocannabinoid engagement of CB2 regulates RSV-induced immunity.

Authors:  Barbara L F Kaplan
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882

Review 9.  Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes.

Authors:  Qing-Rong Liu; Kanikkai Raja Aseer; Qin Yao; Xiaoming Zhong; Paritosh Ghosh; Jennifer F O'Connell; Josephine M Egan
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.